CABALETTA BIO, INC. Debt Conversion, Converted Instrument, Amount
CABALETTA BIO, INC. (CABA) reported Debt Conversion, Converted Instrument, Amount of $18.78 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2020-03-30
- CABALETTA BIO, INC. debt conversion, converted instrument, amount for fiscal 2018 was $18.78M.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2018-12-31 | $18.78M 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |